Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Environmental Factors Instruct Lineage Choice Of Blood Progenitor Cells
The research team led by Dr. Timm Schroeder, stem cell researcher at Helmholtz Zentrum MÃønchen, has developed a new bioimaging method for observing the differentiation of hematopoietic progenitor cells (HPC) at the single-cell level. With this method the researchers were able to prove for the first time that not only cell-intrinsic mechanisms, but also external environmental factors such as growth factors can control HPC lineage choice directly. The findings, published in the current issue of the prestigious journal Science, provide an essential building block for understanding the molecular mechanisms of hematopoiesis and are an important prerequisite for optimizing therapeutic stem cell applications.

Thailand Aims To Halve New HIV Cases By 2011, Prime Minister Says
Thailand has set a goal of reducing by half the number of new HIV cases in the country by 2011, Prime Minister Abhisit Vejjajiva said on Wednesday, TNA/MCOT English News reports. Abhisit was speaking at the opening ceremony of the three-day 12th National Seminar on AIDS, which more than 2,500 HIV-positive people, students, and participants from Thai agencies, private sector groups and international organizations are expected to attend. The seminar will focus on the government"s plan to reduce new cases by 2011 and the national HIV/AIDS action plan."The government"s plan, if successful, will be the result of cooperation from all sides," Abhisit said. He added that statistics indicate that one in four new HIV infections occur among men who have sex with men. In addition, new cases among married women in the country have increased by 30% to 40%, according to Abhisit. He said that he will be involved in a campaign to promote fidelity among married couples in the country (TNA/MCOT English News, 5/27).
News of the day
Registered Dietitians - A Cost Effective Investment In Health For Canadians
Dietitians of Canada (DC) released a report today describing the integral role played by registered dietitians, as members of multi-disciplinary teams that contribute to promoting and supporting health among Canadians. The Role of Registered Dietitians in Primary Health Care: Moving Forward - A National Perspective presents evidence for the cost-effectiveness of nutrition services in the prevention and treatment of chronic conditions such as diabetes, hypertension, cancer and heart disease.
Endocrinology

PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous anesthetic/sedative. Following the successful proof of concept study reported in January 2009, a Phase IIa study (single dose) in patients undergoing endoscopy of the upper gastrointestinal tract and a Phase Ib study (multiple dose) in volunteers undergoing a colonoscopy, were started. The Phase IIa study is designed to evaluate the safety and the success of sedation of CNS 7056, as well as the time to full recovery and discharge, in comparison to the "gold-standard" agent, midazolam. The Phase Ib study will allow PAION to generate additional data on pharmacodynamics and pharmacokinetics. Both studies are aimed to determine dose regimes for the further clinical development. As of today more than 50% of the patients/volunteers, respectively, have been recruited in both trials. On 11 May 2009 positive results of the first part of the Phase Ib trial were reported. The effect of CNS 7056 can be reversed by an established antagonist, flumazenil; no re-sedation of the volunteers was observed. "While we have already demonstrated proof of concept in our earlier Phase I first in man study, we are now looking forward to identify the best dose regimes for the next steps of the clinical program for which we are already initiating preparatory work" commented Dr. Wolfgang Sç¶hngen, PAION"s CEO. The studies are being performed in the US and PAION expects to report results before the end of 2009. About CNS 7056 / REMIMAZOLAM (pINN) CNS 7056 is a new short-acting sedative and general anesthetic that acts on GABAA receptors. The substance was added to PAION"s portfolio by acquiring CeNeS who in turn had acquired the substance from GlaxoSmithKline. CNS 7056 is a water-soluble, rapid and short-acting GABAA receptor modulator interacting with the benzodiazepine site. The clinical proof of concept study, reported in January 2009, showed that, after intravenous administration, CNS 7056 rapidly induces sedation. Importantly the sedative effects rapidly disappear after cessation of administration. The rapid offset of effect of the compound is due to its metabolism by esterase enzymes that are widely distributed throughout the body. Therefore it is anticipated that CNS 7056 can be clinically developed as a sedative agent for day case procedures, the induction and maintenance of anesthesia and ICU sedation. PAION initiated partnering discussions in parallel to the ongoing Phase II in order to accelerate the further development of CNS 7056 for territories outside Japan, where the compound is partnered to Ono Pharmaceuticals. PAION


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009